Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.

Abstract

Hormone replacement therapy (HRT) is effective treatment for postmenopausal bone loss and osteoporosis. However, postmenopausal women with low bone mass fail to respond after a few years of HRT and some postmenopausal women show no bone response to HRT. In these cases, additive therapy is necessary. Bisphosphonates are highly effective in postmenopausal osteoporosis. We investigated the effects of adding etidronate, a bisphosphonate, to HRT. The addition of etidronate to HRT improved bone density (4.40+/-1.12% increase per year) in patients showing no increase or even a decrease after at least 1 year of HRT (5.39+/-2.40% decrease per year).

• Authors: Ken-ichirou Morishige, Toshiya Yamamoto, Kenjiro Sawada, Masahide Ohmichi, Keiichi Tasaka, Yuji Murata
• Journal: Archives of gynecology and obstetrics (Arch Gynecol Obstet) Vol. 268 Issue 2 Pg. 105-6 (Jun 2003) ISSN: 0932-0067 [Print] Germany
• PMID: 12768299 (Publication Type: Journal Article)

Chemical References

• Diphosphonates
• Estrogens, Conjugated (USP)
• Hormones
• Medroxyprogesterone
• Etidronic Acid

Topics

• Absorptiometry, Photon
• Adult
• Aged
• Bone Density (drug effects, physiology)
• Diphosphonates (therapeutic use)
• Drug Therapy, Combination
• Estrogen Replacement Therapy
• Estrogens, Conjugated (USP) (therapeutic use)
• Etidronic Acid (therapeutic use)
• Female
• Hormones (therapeutic use)
• Humans
• Medroxyprogesterone (therapeutic use)
• Middle Aged
• Osteoporosis, Postmenopausal (diagnosis, drug therapy, physiopathology)